2 Reasons to Sell TXG and 1 Stock to Buy Instead
What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many ...
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with ...
10x Genomics’ (TXG) Sell (E+) Rating Reiterated at Weiss Ratings
Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports. A number of ...
10x Genomics gets injunction against Parse Biosciences' ATAC Products
Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.
10x Genomics price target lowered to $15 from $20 at Citi
Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...
JD Supra2h
UPC revocation actions: What is a reasonable number of auxiliary requests?
Two recent UPC decisions have provided some guidance on the admissibility and reasonableness of auxiliary requests in revocation actions. The ...
Investing10d
10x Genomics secures injunction against Parse Biosciences
PLEASANTON, Calif. - In a significant development in the biotechnology patent landscape, 10x Genomics Inc. (NASDAQ:TXG), currently valued at $1.2 billion, has successfully obtained a worldwide ...
Morningstar9d
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.